Analyst Alerts Archives - Page 31 of 37

ThursdayMar 30, 2017 1:08 pm

NetworkNewsBreaks – Tonix Pharmaceuticals (NASDAQ: TNXP) Prices Public Offering, Initiates Enrollment in HONOR Study

Tonix Pharmaceuticals (NASDAQ: TNXP) this morning released the pricing of an underwritten public offering of 1,800,000 shares of its common stock at a public offering price of $4.45 per share, for estimated gross proceeds of $8,010,000. The offering is expected to close on or about April 4, 2017, subject to customary closing conditions. Tonix intends to use the net proceeds for many projects, including the further development of pipeline programs, working capital and other general purposes, and to support the continued development of TNX-102 SL. Yesterday, Tonix said that Seth Lederman, M.D., president and chief executive officer will provide a…

ThursdayMar 30, 2017 11:28 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $8 PT on Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $8 on Matinas BioPharma (NYSE: MTNB). Aegis cited positive results from the company’s phase 1 clinical trial of the safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin used to treat different types of chronic and acute bacterial infections. Although mild adverse events on the gastrointestinal system were reported, they decreased when the drug was administered with food. No serious adverse events were reported. Aegis also noted recent, critical comments posted to a financial website, which the analyst believes to be incorrect and responsible for recent volatility…

WednesdayMar 29, 2017 1:14 pm

NetworkNewsBreaks – Recro Pharma, Inc. (NASDAQ: REPH) Receives ‘Buy’ Rating at Aegis Capital, PT Adjusted to $11

Aegis Capital has issued a ‘Buy’ rating and an adjusted price target of $11 on shares of Recro Pharma’s (NASDAQ: REPH) stock. Aegis lowered the price target to $11 from $25 as a result of the recent dilutive capital raise. Recro recently reported financial results for the year ended December 31, 2016. For the fourth quarter of 2016, the company reported revenue of $17.4 million, surpassing street consensus estimates of $13.8 million. Additionally, over the past year, the company has reported positive data for IV Meloxicam from two pivotal phase 3 trials, which Aegis cited as a catalyst for the…

WednesdayMar 29, 2017 1:11 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Receives ‘Buy’ Rating, $14 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and $14 price target on shares of Novocure’s (NASDAQ: NVCR) stock. The report cites the company’s 151% growth in net revenues from 2015 to 2016 and attributes this growth primarily to Novovure’s Tumor Treating Fields (TTFields) technology. TTTFields have been approved for use in the U.S. and internationally for treating glioblastoma (GBM) patients. The company has big plans for 2017, including continuous market adoption in the U.S. and geographical expansion in Germany and Japan. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment centered…

FridayMar 24, 2017 11:27 am

NetworkNewsBreaks – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Receives ‘Buy’ Rating, $12 PT

Aegis Capital recently issued a ‘Buy’ rating and price target of $12 on shares of Corbus Pharmaceuticals Holdings (NASDAQ: CRBP). The company’s fourth quarter was marked by positive data from its phase 2 study of anabasum (previously Resunab or JBT-101) for the treatment of systemic sclerosis showing clear signal of clinical benefit. On March 13, Corbus held a Research and Development day and said the anticipated data from the phase 2a study in cystic fibrosis is on schedule for announcement during March 2017. Aegis cited this data as a possible milestone to drive shares of the company’s stock. For more…

FridayMar 24, 2017 11:23 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Aegis Capital recently reiterated a ‘Buy’ rating and price target of $11 on shares of Conatus Pharmaceuticals (NASDAQ: CNAT). The company’s recent exclusive option, collaboration and license agreement with Novartis (NYSE: NVS) for the global development and commercialization of its lead product emricasan is cited as a positive catalyst by Aegis. For more information, visit www.conatuspharma.com About Conatus Pharmaceuticals Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity…

FridayMar 24, 2017 11:21 am

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Issued ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $8 on shares of Ritter Pharmaceuticals (NASDAQ: RTTR). The company recently modified the primary endpoint of its phase 2b/3 clinical trial of RP-G28, following a meeting with the FDA, in hopes of being considered as a pivotal trial, which would shorten the time frame to approval and revenues. The report by Aegis cites the anticipated release of results from the phase 2b/3 clinical trial of RP-G28, which is expected by the end of the month. For more information, visit www.ritterpharma.com About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. develops novel therapeutic products…

FridayMar 24, 2017 11:15 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on ViewRay, Inc. (NASDAQ: VRAY)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $11 on shares of ViewRay, Inc. (NASDAQ: VRAY). The action follows the release of ViewRay’s financial results, including fourth-quarter 2016 revenue of $16.1 million. Operating costs for the quarter were $9.3 million, down from $10.7 million for the fourth quarter of 2015. ViewRay also provided an outlook for 2017, including an update on the MRIdian LINAC system. The company reported a clear increase in interest in the system after receiving FDA approval in February. Orders are anticipated to further increase in 2017, driving revenue for the year. For more…

WednesdayMar 22, 2017 12:32 pm

NetworkNewsBreaks – SeeThruEquity Issues Update on FTE Networks, Inc. (FTNW), Increases PT to $2.75

SeeThruEquity has issued an update and increased the price target to $2.75 on shares of FTE Networks’ (OTCQX: FTNW) stock. The update follows the company’s March 9th announcement that it plans to acquire Benchmark Builders, Inc. in a $75 million cash and stock transaction that is expected to close in the second quarter of 2017. In February, FTE filed an application to uplist to the Nasdaq Capital Markets, which is cited in the update by SeeThruEquity as a reason to increase the company’s price target. If approved, being listed on the Nasdaq Capital Market would be a noteworthy development for…

TuesdayMar 21, 2017 1:04 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Reiterated with “Buy” Rating, $10 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $10 on shares of Celldex Therapeutics’ (NASDAQ: CLDX) stock. The news follows the company’s report of business and financial highlights for the fourth quarter and year-ended December 31, 2016. The company reported total revenue of $1.9 million in the fourth quarter of 2016, and full-year revenue of $6.8 million, compared to $1.8 million and $5.5 million for the comparable periods in 2015. The company credited the increase in revenue to its clinical trial collaboration with Bristol-Myers Squibb. The company also provided an update on its pipeline, including the increase…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Breaks Categories: Analyst Alerts